Interpace Biosciences — Third Quarter 2026 Earnings Summary
Interpace Biosciences reported third-quarter 2026 revenue of $10.4 million, representing an 18% year-over-year increase driven by a 7% rise in thyroid test volume. The company achieved an adjusted EBITDA of $2.1 million, or 20% of revenue, despite reporting a loss from continuing operations of $1.5 million due to $4.1 million in non-recurring stock compensation and legal expenses. Gross margin expanded to 69% for the quarter, supported by an 11% increase in average revenue per test and operational efficiency gains. The firm continues to operate as a thyroid-only diagnostics provider following the discontinuation of its PancraGEN pancreatic testing business in May 2025, while developing a new pancreatic cancer program expected to generate no revenue in 2026 or 2027.
- Company
- INTERPACE BIOSCIENCES INC
- Sector
- Healthcare
- Industry
- Diagnostics & Research